Procaps Group (PROC) Competitors $1.51 +0.02 (+1.34%) (As of 12/6/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends PROC vs. TECX, DNTH, ANAB, ORIC, TRML, ABUS, TSHA, STOK, EXAI, and GLUEShould you be buying Procaps Group stock or one of its competitors? The main competitors of Procaps Group include Tectonic Therapeutic (TECX), Dianthus Therapeutics (DNTH), AnaptysBio (ANAB), ORIC Pharmaceuticals (ORIC), Tourmaline Bio (TRML), Arbutus Biopharma (ABUS), Taysha Gene Therapies (TSHA), Stoke Therapeutics (STOK), Exscientia (EXAI), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Procaps Group vs. Tectonic Therapeutic Dianthus Therapeutics AnaptysBio ORIC Pharmaceuticals Tourmaline Bio Arbutus Biopharma Taysha Gene Therapies Stoke Therapeutics Exscientia Monte Rosa Therapeutics Tectonic Therapeutic (NASDAQ:TECX) and Procaps Group (NASDAQ:PROC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends. Is TECX or PROC more profitable? Procaps Group's return on equity of 0.00% beat Tectonic Therapeutic's return on equity.Company Net Margins Return on Equity Return on Assets Tectonic TherapeuticN/A -35.53% -31.97% Procaps Group N/A N/A N/A Does the MarketBeat Community believe in TECX or PROC? Tectonic Therapeutic received 4 more outperform votes than Procaps Group when rated by MarketBeat users. Likewise, 100.00% of users gave Tectonic Therapeutic an outperform vote while only 37.50% of users gave Procaps Group an outperform vote. CompanyUnderperformOutperformTectonic TherapeuticOutperform Votes7100.00% Underperform VotesNo VotesProcaps GroupOutperform Votes337.50% Underperform Votes562.50% Which has more risk and volatility, TECX or PROC? Tectonic Therapeutic has a beta of 2.6, suggesting that its stock price is 160% more volatile than the S&P 500. Comparatively, Procaps Group has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Do analysts prefer TECX or PROC? Tectonic Therapeutic presently has a consensus target price of $72.25, suggesting a potential upside of 40.37%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, research analysts clearly believe Tectonic Therapeutic is more favorable than Procaps Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tectonic Therapeutic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Procaps Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation & earnings, TECX or PROC? Procaps Group has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Procaps Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTectonic TherapeuticN/AN/A$12.16M-$5.89-8.74Procaps Group$409.92MN/A$42.54M$0.522.90 Do insiders and institutionals hold more shares of TECX or PROC? 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 9.2% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 19.9% of Procaps Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to TECX or PROC? In the previous week, Tectonic Therapeutic had 1 more articles in the media than Procaps Group. MarketBeat recorded 4 mentions for Tectonic Therapeutic and 3 mentions for Procaps Group. Tectonic Therapeutic's average media sentiment score of 1.03 beat Procaps Group's score of -0.03 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Procaps Group 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTectonic Therapeutic beats Procaps Group on 10 of the 17 factors compared between the two stocks. Ad ProsperityPubWith the “Bitcoin Loophole” you can help supercharge the gains by 10x or more!You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history! That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords… Heck, you don’t even need a crypto wallet!>> Tap here to sign up and join them for the imminent workshop Get Procaps Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PROC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PROC vs. The Competition Export to ExcelMetricProcaps GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$6.76B$5.32B$9.18BDividend YieldN/A8.03%5.77%4.02%P/E Ratio2.905.0883.8113.67Price / SalesN/A344.641,246.0878.01Price / Cash3.0058.0543.1038.50Price / Book-75.505.464.844.98Net Income$42.54M$152.76M$120.54M$225.13M7 Day PerformanceN/A1.62%0.55%0.79%1 Month Performance-9.58%-2.48%0.14%5.51%1 Year Performance-51.60%28.47%33.81%31.47% Procaps Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PROCProcaps Group0.6776 of 5 stars$1.51+1.3%N/A-49.5%$0.00$409.92M2.905,500TECXTectonic Therapeutic3.4193 of 5 stars$49.90+0.2%$72.25+44.8%N/A$736.18MN/A-8.45120DNTHDianthus Therapeutics2.0109 of 5 stars$24.60+2.5%$46.43+88.7%+134.3%$728.16M$2.83M-9.6080Short Interest ↑Positive NewsANABAnaptysBio2.3628 of 5 stars$23.29-6.7%$54.64+134.6%+54.5%$708.72M$17.16M-3.82100ORICORIC Pharmaceuticals3.9128 of 5 stars$9.85-0.5%$18.29+85.6%+10.6%$695.09MN/A-5.5080Positive NewsTRMLTourmaline Bio2.397 of 5 stars$25.76-1.1%$65.00+152.3%+37.0%$660.49MN/A-9.1344Analyst ForecastNews CoveragePositive NewsGap UpABUSArbutus Biopharma2.8344 of 5 stars$3.48+0.6%$5.50+58.0%+78.6%$659.43M$18.14M-8.0573TSHATaysha Gene Therapies3.9087 of 5 stars$3.19-1.5%$6.63+107.7%+45.9%$653.77M$9.92M5.14180News CoverageSTOKStoke Therapeutics3.8267 of 5 stars$12.22+0.9%$20.83+70.5%+215.2%$647.29M$8.78M-5.77100Insider TradeNews CoveragePositive NewsEXAIExscientia2.5703 of 5 stars$4.84+3.2%$7.00+44.6%-23.5%$632.93M$25.60M-3.21280Positive NewsHigh Trading VolumeGLUEMonte Rosa Therapeutics2.3714 of 5 stars$10.20-1.5%$16.00+56.9%+215.8%$626.66M$14.98M-5.7190News Coverage Related Companies and Tools Related Companies Tectonic Therapeutic Alternatives Dianthus Therapeutics Alternatives AnaptysBio Alternatives ORIC Pharmaceuticals Alternatives Tourmaline Bio Alternatives Arbutus Biopharma Alternatives Taysha Gene Therapies Alternatives Stoke Therapeutics Alternatives Exscientia Alternatives Monte Rosa Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PROC) was last updated on 12/7/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Procaps Group S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Procaps Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PROC Stock Alerts